Chimin(SH:603222)2026-01-23 07:50Financial Performance Forecast - The company expects a net loss attributable to shareholders of the parent company for 2025 to be between -210 million and -250 million CNY, an increase in loss compared to the previous year's loss of -59.71 million CNY[4] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -205 million and -245 million CNY[4] - The previous year's net profit attributable to shareholders was -59.71 million CNY, with a net profit of -58.69 million CNY after deducting non-recurring gains and losses[6] Impairment Provisions - The company plans to recognize an inventory impairment provision of approximately 37 million CNY for its pre-filled catheter flushing devices and safety syringes[8] - A goodwill impairment provision of approximately 20 million CNY will be recognized for the Ezhou Second Hospital due to a decline in performance compared to the previous year[8] - Cumulative goodwill impairment provisions for the Ezhou Second Hospital will total approximately 136.34 million CNY, with a remaining book value of about 15.14 million CNY[8] Impact of External Factors - The company’s revenue has further declined due to the impact of U.S. tariff policies and the "He Qinghong seal forgery incident," leading to increased losses[8] Financial Reporting and Auditing - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by certified public accountants[9] - Investors are advised that the above forecast data is preliminary and the accurate financial data will be disclosed in the audited 2025 annual report[10]